Federated Hermes Inc. Trims Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Federated Hermes Inc. lessened its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 5.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 746,499 shares of the company's stock after selling 41,248 shares during the quarter. Federated Hermes Inc. owned 1.59% of Omnicell worth $26,098,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of OMCL. Lazard Asset Management LLC increased its position in Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after buying an additional 737,536 shares in the last quarter. Toronto Dominion Bank purchased a new stake in Omnicell in the fourth quarter worth about $30,637,000. Dimensional Fund Advisors LP increased its position in Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after buying an additional 394,820 shares in the last quarter. Oberweis Asset Management Inc. purchased a new stake in Omnicell in the fourth quarter worth about $14,834,000. Finally, Pacer Advisors Inc. purchased a new stake in Omnicell in the first quarter worth about $10,542,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on OMCL. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Bank of America upped their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Wells Fargo & Company upped their price objective on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Benchmark dropped their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $45.33.

Omnicell Price Performance

Omnicell stock traded down $1.25 during midday trading on Friday, reaching $29.76. 742,476 shares of the stock traded hands, compared to its average volume of 500,803. The stock's fifty day moving average is $29.27 and its 200-day moving average is $33.18. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The stock has a market cap of $1.39 billion, a P/E ratio of 59.52, a PEG ratio of 9.05 and a beta of 0.76. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. The company's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the company earned $0.51 EPS. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.